Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Beyond these primary endpoints, TRIUMPH-1 includes a range of secondary and exploratory endpoints that paint a fuller picture of retatrutide's clinical impact: Proportion of participants achieving 10%, 15%, and 20% or greater weight loss Changes in waist circumference Changes in cardiometabolic risk factors, including blood pressure, triglycerides, HDL cholesterol, LDL cholesterol, and fasting glucose Changes in HbA1c (a measure of average blood sugar over the preceding two to three months) Changes in liver enzymes and markers of hepatic health Patient-reported outcomes related to quality of life and physical function Safety and tolerability, including the incidence and severity of adverse events The secondary endpoints are particularly important for retatrutide because the Phase 2 data showed striking improvements across metabolic markers
Antiporter activity is an important factor in the first pass metabolism of pharmaceuticals and other xenobiotics
Between busy schedules and lower appetites, it can be tempting to skip healthy meals and snacks while on a GLP-1 diet
Everyone was so kind and efficient
Additionally, aminorex and sibutramine have been linked to cardiovascular toxicity, pulmonary hypertension, and a rise in non-fatal cardiovascular incidents [37, 39, 43, 45, 46]
